1. Home
  2. AUPH vs PAHC Comparison

AUPH vs PAHC Comparison

Compare AUPH & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • PAHC
  • Stock Information
  • Founded
  • AUPH 1993
  • PAHC 1946
  • Country
  • AUPH Canada
  • PAHC United States
  • Employees
  • AUPH N/A
  • PAHC N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • PAHC Biotechnology: Pharmaceutical Preparations
  • Sector
  • AUPH Health Care
  • PAHC Health Care
  • Exchange
  • AUPH Nasdaq
  • PAHC Nasdaq
  • Market Cap
  • AUPH 1.1B
  • PAHC 968.3M
  • IPO Year
  • AUPH 1999
  • PAHC 2014
  • Fundamental
  • Price
  • AUPH $8.77
  • PAHC $25.61
  • Analyst Decision
  • AUPH Strong Buy
  • PAHC Sell
  • Analyst Count
  • AUPH 2
  • PAHC 4
  • Target Price
  • AUPH $11.50
  • PAHC $21.25
  • AVG Volume (30 Days)
  • AUPH 1.4M
  • PAHC 235.7K
  • Earning Date
  • AUPH 07-31-2025
  • PAHC 05-07-2025
  • Dividend Yield
  • AUPH N/A
  • PAHC 1.89%
  • EPS Growth
  • AUPH N/A
  • PAHC 140.17
  • EPS
  • AUPH 0.27
  • PAHC 0.78
  • Revenue
  • AUPH $247,295,000.00
  • PAHC $1,190,682,000.00
  • Revenue This Year
  • AUPH $12.15
  • PAHC $28.33
  • Revenue Next Year
  • AUPH $18.31
  • PAHC $13.78
  • P/E Ratio
  • AUPH $31.76
  • PAHC $32.60
  • Revenue Growth
  • AUPH 29.20
  • PAHC 19.12
  • 52 Week Low
  • AUPH $5.20
  • PAHC $16.16
  • 52 Week High
  • AUPH $10.67
  • PAHC $26.55
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 66.00
  • PAHC 67.45
  • Support Level
  • AUPH $7.71
  • PAHC $24.59
  • Resistance Level
  • AUPH $8.29
  • PAHC $25.37
  • Average True Range (ATR)
  • AUPH 0.25
  • PAHC 0.74
  • MACD
  • AUPH 0.03
  • PAHC -0.01
  • Stochastic Oscillator
  • AUPH 84.40
  • PAHC 97.23

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Share on Social Networks: